GLP-1 Medication and Fertility: What Changes May Mean

Some people notice changes in their menstrual cycle while taking a GLP-1 medicine, and social media is full of surprise-pregnancy stories. Those experiences deserve a careful conversation, but they don't prove that a medicine directly boosts fertility. Weight change, conditions like PCOS, age, contraception and other factors can all affect reproductive health at the same time.

What is known, and what is not

Most of the research comes from small trials in women with polycystic ovary syndrome (PCOS), often using older GLP-1 medicines like liraglutide. Meta-analyses of those trials report more regular periods and better insulin-resistance markers, and one 2023 analysis of 11 small trials found a higher natural pregnancy rate, though overall and IVF pregnancy rates weren't clearly different. A 2026 liraglutide review couldn't pool ovulation or pregnancy results at all because too few trials reported them.

So more regular cycles or better metabolic markers aren't the same thing as a proven increase in live births. A fertility claim needs direct evidence on fertility outcomes, and for most people and most medicines, that evidence doesn't exist yet. Our PCOS evidence guide covers those studies in more detail.

Two practical reasons for "surprise" pregnancies

First, if cycles become more regular, ovulation may return, sometimes before someone expects it.

Second, some of these medicines can affect birth-control pills. The US labels for Zepbound and Mounjaro (tirzepatide) say they may make oral hormonal contraceptives less effective, because they slow stomach emptying. The labels advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase. The Foundayo (orforglipron) label gives similar advice for 30 days after starting and after each increase. Non-oral hormonal methods aren't expected to be affected. Semaglutide labels (Ozempic, Wegovy) don't carry this advice, which is a good example of why one product's instructions can't be applied to another.

Pregnancy is a separate safety question

Weight-loss medicines aren't recommended during pregnancy. The US Wegovy label, for example, says to stop it when pregnancy is recognized and to stop at least 2 months before a planned pregnancy because semaglutide lingers in the body. The Zepbound label says weight loss offers no benefit during pregnancy and may cause fetal harm, and to stop when pregnancy is recognized. If pregnancy happens while taking a prescription medicine, contact the prescribing clinician promptly for individual advice rather than deciding alone.

Could weight change alter cycles?

Weight and insulin-resistance changes can affect menstrual function in some people, particularly with PCOS. But a missed or changed period can also come from pregnancy, stress, thyroid conditions, rapid weight loss and other causes that may need checking. Jotting cycle changes down alongside other symptoms (see what to track on a GLP-1) makes them easier to discuss.

What to ask

Tell your clinician if pregnancy is a goal, if you use the pill, or if your cycle changes. Useful questions include: which treatments fit with my reproductive plans? How far ahead of trying to conceive should this medicine be stopped? Does it affect my contraception? What else can support the underlying condition?

The central message is practical: fertility questions are best discussed before treatment choices, not after a social-media surprise. The evidence is still developing, and individual planning matters more than online promises.